StocksMedium•28 September 2026•
1 min read
SCYNEXIS Awarded $214M BARDA Contract for Antifungal SCY-247 Development
Key Facts
1SCYNEXIS was awarded a contract by BARDA to advance the development of its antifungal candidate SCY-247.
2The contract provides up to $214 million in non-dilutive funding for the company.
SCYNEXIS was awarded a contract by the U.S. Biomedical Advanced Research and Development Authority (BARDA) to advance the development of its antifungal candidate SCY-247. GlobeNewswire reported that the contract provides up to $214 million in non-dilutive funding, intended to support medical countermeasures against severe rare diseases and fungal threats.
SCYX closed at $4.39 on September 25, 2026, with the stock reaching a day high of $4.58 and a low of $4.37 during that session. This government funding validates the company's clinical pipeline and extends its cash runway without diluting existing shareholders.